Grants per year
Personal profile
Research Interests
Dr. Laumann's clinical interests include the diagnosis and treatment of complex medical dermatologic disorders including collagen vascular, psychocutaneous, and genital diseases. She has a particular interest in fibrosing, pruritic and other disorders related to renal dysfunction, as well as Raynaud's syndrome. She has an ongoing interest in the various aspects of the application of body art and how this may be used to help functioning. Currently, she is involved with other research studies related to psoriasis, atopic dermatitis, nephrogenic systemic fibrosis, systemic sclerosis, morphea, dermatomyositis, and lupus erythematosus.
Certifications and Licenses
| Dermatology |
Training Experience
| 1979 | Residency, University of Chicago Hospitals |
Education/Academic qualification
MRCP (UK), Royal College of Physicians of the UK
… → 1973
MBChB, University of Birmingham
… → 1968
Research interests
- Dermatology
Fingerprint
Dive into the research topics where Anne E Laumann is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Grants
- 30 Finished
-
Prot #GS-US-436-4092: A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Filgotinib and GS-9876 in Female Subjects with Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE)
ICON Clinical Research, L.P., Gilead Sciences, Inc.
7/27/17 → 7/27/20
Project: Research project
-
Prot #8400-211: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of IMO-8400 In Patients with Dermatomyositis
Parexel, Idera Pharmaceuticals, Inc.
3/14/16 → 3/14/19
Project: Research project
-
Prot #CC-220-SLE-001: A PILOT, PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, STUDY TO EVALUATE EFFICACY, SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND PHARMACOGENETICS OF CC-220 IN SUBJECTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
PPD Development, Celgene Corporation
4/7/15 → 4/7/19
Project: Research project
-
Prot #X052171: A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Patients with Pyoderma Gangrenosum
Therapeutics, Inc., XOMA (US) LLC
3/19/15 → 3/19/18
Project: Research project
-
Effect of Costimulatory Blockade with Abatacept after Ustekinumab Withdrawal in Patients with Moderate to Severe Plaque Psoriasis: The PAUSE Randomized Clinical Trial
Harris, K. M., Smilek, D. E., Byron, M., Lim, N., Barry, W. T., McNamara, J., Garcet, S., Konrad, R. J., Stengelin, M., Bathala, P., Korman, N. J., Feldman, S. R., Boh, E. E., Barber, K., Laumann, A. E., Helfrich, Y. R., Krueger, G. G., Sofen, H., Bissonnette, R. & Krueger, J. G., Nov 2021, In: JAMA dermatology. 157, 11, p. 1306-1315 10 p.Research output: Contribution to journal › Article › peer-review
Open Access4 Scopus citations -
Developing classification criteria for skin-predominant dermatomyositis: the Delphi process
The Skin Myositis Delphi Group, Feb 1 2020, In: British Journal of Dermatology. 182, 2, p. 410-417 8 p.Research output: Contribution to journal › Article › peer-review
13 Scopus citations -
Evaluation of the Effectiveness and Tolerability of Mycophenolate Mofetil and Mycophenolic Acid for the Treatment of Morphea
Arthur, M., Fett, N. M., Latour, E., Jacobe, H., Kunzler, E., Florez-Pollack, S., Houser, J., Sharma, S., Prasad, S., Femia, A., Stern, M. J., Pappas-Taffer, L. K., Gaffney, R., Fernandez, A. P., Knabel, D., Cardones, A. R., Leung, N., Laumann, A., Yu, J. M., Zhao, J., & 3 others, May 2020, In: JAMA dermatology. 156, 5, p. 521-528 8 p.Research output: Contribution to journal › Article › peer-review
8 Scopus citations -
Association of dermatomyositis with systemic and opportunistic infections in the United States
Ren, Z., Laumann, A. E. & Silverberg, J. I., Jul 5 2019, In: Archives of Dermatological Research. 311, 5, p. 377-387 11 p.Research output: Contribution to journal › Article › peer-review
9 Scopus citations -
Melanoma subsequent to natalizumab exposure: A report from the RADAR (Research on Adverse Drug events And Reports) program
Kelm, R. C., Hagstrom, E. L., Mathieu, R. J., Orrell, K. A., Serrano, L., Mueller, K. A., Laumann, A. E., West, D. P. & Nardone, B., Mar 2019, In: Journal of the American Academy of Dermatology. 80, 3, p. 820-821 2 p.Research output: Contribution to journal › Article › peer-review
Open Access4 Scopus citations